{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:58:32Z","timestamp":1773701912329,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The efficacy of factor Xa\ninhibitors in patients with atrial fibrillation (AF) and rheumatic heart\ndisease\u00a0(RHD) is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/Results<\/jats:title>\n                <jats:p>The objective of this article was to conduct a comprehensive evaluation of the INVICTUS trial, an open-label randomized controlled study that compared vitamin K antagonists (VKA) to rivaroxaban in\u00a0patients with AF and RHD\u00a0while also considering the existing evidence from literature in this particular\u00a0area of research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings of the INVICTUS trial indicated that rivaroxaban was found to be inferior in efficacy to\u00a0VKA. However, it is important to note that the primary outcome of the trial was driven by sudden death\u00a0and death caused by mechanical pump failure. As a result, it is necessary to approach the data from this\u00a0study with caution, and it would be inappropriate to draw parallel conclusions for other causes of\u00a0valvular AF. Particularly, the perplexing issue of how rivaroxaban could have contributed to both pump\u00a0failure and sudden cardiac death requires further explanation. Additional data regarding changes in heart\u00a0failure medication and ventricular function would be essential for proper interpretation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-023-07470-z","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T05:01:38Z","timestamp":1684990898000},"page":"1065-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rivaroxaban in Valvular Atrial Fibrillation \u2014 a Critical Appraisal of the INVICTUS Trial"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-1085","authenticated-orcid":false,"given":"Andreas","family":"Hammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Sulzgruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"5","key":"7470_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"issue":"2","key":"7470_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ehjcvp\/pvv002","volume":"1","author":"R Hinojar","year":"2015","unstructured":"Hinojar R, Jim\u00e9nez-Natcher JJ, Fern\u00e1ndez-Golf\u00edn C, Zamorano JL. New oral anticoagulants: a practical guide for physicians. European Heart J - Cardiovasc Pharmacother. 2015;1(2):134\u201345.","journal-title":"European Heart J - Cardiovasc Pharmacother"},{"issue":"11","key":"7470_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","volume":"387","author":"SJ Connolly","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease\u2013associated atrial fibrillation. N Engl J Med. 2022;387(11):978\u201388.","journal-title":"N Engl J Med"},{"issue":"10","key":"7470_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/eurjhf\/hft095","volume":"15","author":"F Zannad","year":"2013","unstructured":"Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15(10):1082\u201394.","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"7470_CR5","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","volume":"116","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482\u20137.","journal-title":"Circulation"},{"issue":"7","key":"7470_CR6","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1016\/S2214-109X(17)30196-1","volume":"5","author":"H Dokainish","year":"2017","unstructured":"Dokainish H, Teo K, Zhu J, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health. 2017;5(7):e665\u201372.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"7470_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cardfail.2016.09.016","volume":"23","author":"MU Sani","year":"2017","unstructured":"Sani MU, Cotter G, Davison BA, et al. Symptoms and Signs of Heart Failure at Admission and Discharge and Outcomes in the sub-Saharan Acute Heart Failure (THESUS-HF) Registry. J Card Fail. 2017;23(10):739\u201342.","journal-title":"J Card Fail"},{"issue":"6","key":"7470_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ehjcvp\/pvab033","volume":"7","author":"P Ameri","year":"2021","unstructured":"Ameri P, Bertero E, Maack C, et al. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? European Heart J - Cardiovasc Pharmacother. 2021;7(6):539\u201346.","journal-title":"European Heart J - Cardiovasc Pharmacother"},{"issue":"7","key":"7470_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2021","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;43(7):561\u2013632.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07470-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07470-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07470-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:05:30Z","timestamp":1727496330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07470-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7470"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07470-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"9 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Patrick Sulzgruber: reports grants from Daiichi Sankyo, grants from Astra Zeneca and grants personal fees from Boehringer-Ingelheim outside the submitted work; Alexander Niessner: reports personal fees from Bayer, personal fees from BMS, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Daiichi Sankyo and personal fees from Pfizer outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}